Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.
We retrospectively evaluated the outcome of 156 adults age 17-60 with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-inspired protocol. The CR rate was 93%; 5-year overall survival (OS) and disease-free survival were 66% and 70%, respectively. Age <34 years and low presenting WBC were independent predictors of favorable OS (p<0.0001). The 5 year OS of patients age <34 and 34-60 presenting with a low WBC were 85% and 57%, respectively; the 5 year OS for those presenting with a high WBC were 57% and 30%, respectively. Cytogenetics and phenotype were not independent predictors of OS.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: joseph.brandwein@albertahealthservices.ca.
Joseph M
JM
Brandwein
Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Eshetu G
EG
Atenafu
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Andre C
AC
Schuh
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Karen W L
KW
Yee
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Aaron D
AD
Schimmer
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Vikas
V
Gupta
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Mark D
MD
Minden
D000293:Adolescent; D000328:Adult; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome
D016044:Fusion Proteins, bcr-abl
Acute lymphoblastic leukemia; Chemotherapy; Leukemia; Prognostic factors